Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Travere Therapeutics ( (TVTX) ) has provided an announcement.
On April 13, 2026, Travere Therapeutics announced that the U.S. Food and Drug Administration approved FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 and older with focal segmental glomerulosclerosis without nephrotic syndrome. The drug becomes the first and only FDA-approved treatment for FSGS, extending FILSPARI’s reach beyond IgA nephropathy and opening an estimated U.S. addressable market of more than 30,000 patients.
The approval is supported by the Phase 3 DUPLEX Study, the largest interventional trial in FSGS, in which FILSPARI showed significantly greater reductions in proteinuria and a favorable effect on eGFR versus maximum-dose irbesartan over 108 weeks, with a comparable safety profile in both adult and pediatric patients. This milestone strengthens Travere’s position in rare kidney disease therapeutics and may materially influence treatment standards for FSGS patients who previously lacked an approved therapy.
The most recent analyst rating on (TVTX) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.
Spark’s Take on TVTX Stock
According to Spark, TipRanks’ AI Analyst, TVTX is a Neutral.
The score is held down primarily by weak financial strength (ongoing net losses and high leverage) and soft technical momentum, partially offset by a constructive earnings update highlighting strong FILSPARI commercial growth and improved near-term profitability/cash position despite regulatory timing and expense headwinds.
To see Spark’s full report on TVTX stock, click here.
More about Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare kidney diseases. Its lead product FILSPARI (sparsentan) targets conditions such as IgA nephropathy and focal segmental glomerulosclerosis, positioning the company in specialized nephrology markets with significant unmet medical needs.
Average Trading Volume: 1,519,696
Technical Sentiment Signal: Buy
Current Market Cap: $2.67B
See more insights into TVTX stock on TipRanks’ Stock Analysis page.